Pharma Marketing Network

eDetailing proponents, inside pharma companies and outside, use survey data to justify their arguments for greater spending on eDetails. In some cases, however, the numbers seem to show confusing trends and even may suggest that eDetailing may not be all that it's cracked up to be.

You've probably seen ads on TV and in print for several new drugs to treat insomnia. FDA-approved drugs for this condition include AMBIEN (Sanofi-Aventis),...

Leverage Mobile Detailing to Deliver Targeted, Engaging and Valuable Product Information to Physicians

Join us at the leading event for medical device marketing to hear more high-level, informative presentations and gain insight into new regulatory compliance updates, key marketing techniques and ROI models for successful DTC campaigns.

Hear from Rx, OTC, medical device companies and leading industry associations about how to examine and minimize potential liability issues, prepare for the logistical aspects of a recall and evaluate whether to outsource the recall process.

Distinguish lawful off-label communication from illegal off-label promotion

In November, the FDA will host a 2-day public meeting on direct-to-consumer (DTC) promotion of regulated products, including prescription drugs. According to the September...

Featured Conference Forum on Disease Awareness and Patient Education for the Pharmaceutical Industry September 22 -...

Attend CBI's annual conference and gain insight from the regulatory, clinical, marketing, adverse events and Post-Marketing perspectives.  The program provides a unique forum in which you can network with industry executives and Phase IV teams who can share their valuable experiences with you.

This conference provides insights into the economic implications of poor disease management and patient non-compliance.